Boundless Bio (BOLD) Company Report

Boundless Bio is a precision oncology company focused on addressing unmet needs in patients with oncogene amplification-driven tumors, which account for approximately 25% of all cancer patients, by targeting extrachromosomal DNA (ecDNA).
The company currently has two programs, BBI-355 and BBI-825, in ongoing clinical trials and is preparing to file an Investigational New Drug (IND) application for a third program, BBI-940, with a planned first-in-human study in the first half of 2026.
BBI-940 is described as a first-in-class oral degrader of a novel kinesin target, identified through their proprietary Spyglass platform, showing promising preclinical anti-tumor activity, particularly in breast cancer models.
As of its last earnings report, Boundless Bio had approximately $117 million in cash, projecting a financial runway into 2028.

Dec 3, 2025, 2:30 PM

Boundless Bio Provides Update on ecDNA Oncology Programs and Financial Runway

BOLD

New Projects/Investments

Guidance Update

Boundless Bio is a precision oncology company focused on addressing unmet needs in patients with oncogene amplification-driven tumors, which account for approximately 25% of all cancer patients, by targeting extrachromosomal DNA (ecDNA), found in about 15% of all cancers.
The company currently has two programs (BBI-355 and BBI-825) in ongoing clinical trials and is preparing a third program, BBI-940, a first-in-class oral degrader of a novel kinesin, for an Investigational New Drug (IND) submission to enter the clinic in the first half of 2026.
Preclinical data for BBI-940 indicates a favorable therapeutic window and anti-tumor activity, particularly in breast cancer, which is expected to be the initial clinical focus.
As of its last earnings report, Boundless Bio reported approximately $117 million in cash, providing a projected financial runway into 2028.

Dec 3, 2025, 2:30 PM

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

BOLD

Earnings

New Projects/Investments

Guidance Update

Boundless Bio reported a net loss of $13.9 million for the third quarter of 2025, compared to a net loss of $16.5 million for the same period in 2024. Research and Development (R&D) expenses were $10.7 million, and General and Administrative (G&A) expenses were $4.5 million for Q3 2025.
As of September 30, 2025, the company's cash, cash equivalents, and short-term investments totaled $117.6 million. This cash position is projected to support operations into the first half of 2028, covering expected proof-of-concept clinical readouts for both programs.
Enrollment is actively underway in the BBI-355 / BBI-825 combination arm of the POTENTIATE trial. Additionally, the investigational new drug (IND) submission for BBI-940 is on track, with a first-in-human clinical trial expected to initiate in the first half of 2026.